Skip to content
etf.net

Launched · SEC filings

Simplify Propel Opportunities ETF

SURINYSE ArcaSimplifyF

$16.10−0.83 (−4.93%)

As of Nov 2, 2026, 3:59 PM ET

F14/ 100

Rank 125 of 126 in US Active Equity

F14/100Rank 125 of 126inUS Active Equity
Intraday session: down, 79 prints from 16.93 to 16.10. Range 16.10 to 16.97. Use the arrow keys to read each point.16.2016.4016.6016.8010 AM12 PM2 PM4 PM
Expense ratio
2.59%*
Fund size
$74M
1Y total return
+17.7%
Yield · Last 12 months
15.79%
Holdings
39
Avg volume · 30D
4.65K sh
52W range
low $14.90high $21.31
Launched
Filings
SEC EDGAR

*After a fee waiver that ends Oct 31, 2027. Without it: 2.84%.

The ETF.net SURI Grade

Based on 5 of 6 pillars

F

Score 14 out of 100

Category
US Active Equity⁠
Rank
125 of 126
Six-pillar profile for SURI. Scores out of 100: Cost 0, Risk 19, Mission not scored, Tradability 13, Holdings 28, Durability 61. Strongest: Durability (61). Weakest: Cost (0). Based on 5 of 6 pillars.

Score 14 of 100 falls in the F band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    F0 out of 100
    Rank 125 of 126

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    F19 out of 100
    Rank 114 of 126

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    F13 out of 100
    Rank 119 of 126

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    D28 out of 100
    Rank 115 of 124

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    B61 out of 100
    Rank 52 of 126

Our read on SURI

ETF.net Research

In short

FA specialist healthcare stock-picker in an ETF shell. Simplify hands the keys to sub-adviser Propel, whose science team hunts global biotech, pharma, health tech and life-science names it believes investors have overlooked.

Stated mandate

The Fund seeks long-term capital appreciation.

Why people hold it

  • A scientist's mandate, not an index screen: Propel sub-advises, using health sciences expertise to pick the names, and the fund is actively managed rather than tracking a benchmark.simplify.us
  • Narrow on purpose: biotech, pharma, health care technology and life science tools, global in reach, with long-term capital appreciation as the stated objective.
  • Live since 2023, so there is a real record of this team's picks to inspect instead of a backtest, inside standard 1940 Act ETF plumbing that pays quarterly.

Worth knowing

  • 2.56% net of a waiver through May 31, 2027, against 2.81% gross, well above the category median. Concentrated specialist research is what that fee buys.
  • Thinly traded and modest in size, so getting in and out can cost more than with a broad index ETF.
  • One slice of one sector, with no index anchoring it, means outcomes ride on the sub-adviser's judgment.

SURI Holdings

Holdings pillarD28 out of 100Rank 115 of 124 in US Active Equity
Asset class
Stocks
Holdings
39
Top-10 weight
83%
Largest holding
PAGP48.8%

Sectors

  • Health Care50.9%
  • Energy49.1%

Geography

  • United States92.60%
  • Canada3.98%
  • France1.76%
  • United Kingdom1.66%
The fund’s holdings, weight-ordered — page 1 of 3.
#TickerCompanyWeight %SharesMarket valueHeld by ETFs
1PAGPPlains Gp Hldgs L P48.82%1,272,360$36.1M45
2ACHVAchieve Life Sciences Inc USD 0.0018.60%932,105$6.37M39
3No dataAchieve Life Sciences I Wts 30JUN305.00%966,667$3.7M1
4DCTHDelcath Sys Inc USD 0.014.28%225,562$3.17M45
5No dataCash4.27%3,163,058$3.16M104
6MISTMilestone Pharmaceuticals Inc Npv3.30%3,349,379$2.45M2
7COLLCollegium Pharmaceutical USD 0.0013.01%93,521$2.23M113
8CORTCorcept Therapeutics Inc USD 0.0012.25%20,568$1.67M152
9PHATPhathom Pharmaceuticals USD 0.00011.93%249,267$1.43M49
10ABEOAbeona Therapeutics Inc USD 0.011.62%276,333$1.2M40
11OBIOOrchestra Biomed Hldgs I USD 0.00011.56%195,011$1.15M34
12IVAInventiva SA Npv Adr1.55%313,483$1.14M5
13AQSTAquestive Therapeutics In USD 0.0011.47%278,723$1.08M38
14CMPSCompass Pathways PLC USD 0.008 Adr1.41%90,381$1.05M19
15KYTXKyverna Therapeutics In USD 0.000011.40%182,603$1.04M51

Showing 1–15 of 39 holdings

SURI Performance

Launched Feb 7, 2023

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.Not enough history yet.
SURI$11,766
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. SURI $11,766. SPY $11,199. Use the arrow keys to read each point.$10,000$12,000Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for SURI. Periods over one year show the average yearly return.
PeriodSURI
Year to date+16.5%
1 month−1.8%
3 months−0.7%
1 year+17.7%
3 yearsper year+14.3%
5 yearsFund is under 5 years oldper yearNo data
10 yearsFund is under 10 years oldper yearNo data

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for SURI
YearReturn barSURI
2026 YTD+16.5%
2025+28.3%
2024−13.2%
2023−3.0%

Since listing, Feb 7, 2023

SURI in the news

SURI Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
15.79%Last 12 months
Payout per share
$2.72Last 12 months
Last payment
$0.68 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Quarterly

Distribution history

2023–2026

One bar per payment. 15 payments from 2023 to 2026 YTD. Mar 27, 2023 $1.00; Jun 27, 2023 $0.68; Sep 27, 2023 $0.68; Dec 26, 2023 $0.68; Mar 25, 2024 $0.68; Jun 25, 2024 $1.25; Sep 25, 2024 $0.68; Dec 23, 2024 $0.68; Mar 26, 2025 $0.68; Jun 25, 2025 $0.68; Sep 25, 2025 $0.68; Dec 23, 2025 $0.68; Mar 26, 2026 $0.68; Jun 25, 2026 $0.68; Sep 25, 2026 $0.68. Use the arrow keys to read each point.2023202420252026YTD
Ex-datePay dateAmount per share
Sep 25, 2026Sep 30, 2026$0.68
Jun 25, 2026Jun 30, 2026$0.68
Mar 26, 2026Mar 31, 2026$0.68
Dec 23, 2025Dec 31, 2025$0.68
Sep 25, 2025Sep 30, 2025$0.68
Jun 25, 2025Jun 30, 2025$0.68
Mar 26, 2025Mar 31, 2025$0.68
Dec 23, 2024Dec 31, 2024$0.68
Sep 25, 2024Sep 30, 2024$0.68
Jun 25, 2024Jun 28, 2024$1.25
Mar 25, 2024Mar 28, 2024$0.68
Dec 26, 2023Dec 29, 2023$0.68

See all 15 payments⁠

$10,000 in SURI 3 years ago paid $4,521 in dividends.⁠

SURI Risk

Risk pillarF19 out of 100Rank 114 of 126 in US Active Equity
How much the fund’s monthly returns vary, scaled to a year.
30.1%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.45
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−47.7%
44 months · trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
1.18
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

SURI Cost

Compare SURI and TACU

Overpaying vs TACU, cheapest in US Active Equity

$39,625

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • SURI 2.59%

    $39,625

  • TACU 0.00% Cheapest

    $0

$10,000
30 years

Cost over time

  • SURI 2.59%
  • TACU 0.00%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$10K$20K$30K$40K051015202530SURI $39,625TACU $0

Year by year

YearSURITACUOverpaying
10$4,275$0$4,275
20$14,992$0$14,992
30$39,625$0$39,625
How the 2.59% is worked out

Full fee 2.84%− waiver 0.25%= you pay 2.59%

The waiver ends Oct 31, 2027. After that the fee is 2.84% unless Simplify renews it. Source: prospectus, Oct 2026.

Other funds in US Active Equity

See others